Open AccessClinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Author(s) -
James P. Campbell,
Claudia Zierold,
Ashli M. Rode,
Frank Blocki,
Byron P. Vaughn
Publication year - 2020
Publication title -
journal of clinical gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.141
H-Index - 112
eISSN - 1539-2031
pISSN - 0192-0790
DOI - 10.1097/mcg.0000000000001359
Subject(s) - calprotectin , medicine , irritable bowel syndrome , gastroenterology , colonoscopy , inflammatory bowel disease , feces , ulcerative colitis , biomarker , faecal calprotectin , disease , colorectal cancer , paleontology , biochemistry , chemistry , cancer , biology
The goal of this study was to assess the clinical performance of an investigational in vitro fecal calprotectin immunoassay for differentiating inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS).